Kinase News and Research

RSS

Novel compound blocks signaling from protein implicated in many types of cancer

Researchers at New York University's Department of Chemistry and NYU Langone Medical Center have developed a compound that blocks signaling from a protein implicated in many types of cancer. The compound is described in the latest issue of the journal Nature Chemical Biology.

18 Jul 2011

Kinexus introduces new KiNET-Antibody Microarray website

Kinexus Bioinformatics Corporation, a world-leader in molecular intelligence research, announced a major expansion in its KiNET DataBank for the study of cell communication systems with the launch of the KiNET-Antibody Microarray website.

13 Jul 2011

Onconova, SymBio enter commercialization collaboration for rigosertib in Japan and Korea

Onconova Therapeutics, Inc., and SymBio Pharmaceuticals Limited announced today that they will collaborate to develop and commercialize rigosertib in Japan and Korea. Onconova is conducting late-stage clinical trials with rigosertib (ON 01910.Na) in the U.S., Europe and India for the treatment of Myelodysplastic Syndromes (MDS) and solid tumors.

8 Jul 2011

Inhibiting heat shock transcription factor 1 prevents liver cancer in mice

Altering the body's metabolism could be an effective treatment for deadly liver cancer, researchers report.

7 Jul 2011

PET imaging technique may identify TKI-responsive lung cancer

A non-invasive PET imaging technique may identify lung cancers that respond best to tyrosine kinase inhibitors (TKIs), allowing doctors to better select patients for personalized therapy, according to research presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer.

5 Jul 2011

Erlotinib phase III study results on lung cancer presented at IASLC conference

In the first phase III study to include Western lung cancer patients, first-line treatment with erlotinib (Tarceva) nearly doubled progression-free survival compared with chemotherapy, according to research presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer.

5 Jul 2011

Six new scientists to receive SWCRF grants for cancer research

This year, the Samuel Waxman Cancer Research Foundation awarded individual grants to six new researchers in addition to funding 18 collaborative grants and three ongoing individual grants. The Foundation expanded its scientific grants program to a total of more than $3.1 million.

1 Jul 2011

Scientists discover enzyme that can regulate breast cancer development

Researchers at Cold Spring Harbor Laboratory (CSHL) have identified an enzyme that appears to be a significant regulator of breast cancer development. Called PTPN23, the enzyme is a member of a family called protein tyrosine phosphatases, or PTPs, that plays a fundamental role in switching cell signaling on and off.

1 Jul 2011

Protein c-JUN protects both tumour accelerating gene and tumour suppressor gene

The process of cell division is tightly regulated, as mistakes may lead to cancer. The so-called c-JUN protein has been fingered as causing tumours in both skin and liver. It has long been known to have a direct role in reducing the expression of a gene (p53) that leads to the death of abnormal cells and to activate transcription of a further gene (CyclinD1) that directly promotes cell division.

28 Jun 2011

Pfizer to present PF-299 and crizotinib clinical trial data on ALK at WCLC 2011

Pfizer Inc. will present early and mid-stage data from its lung cancer portfolio, including PF-00299804 an investigational, oral, pan-HER inhibitor; and crizotinib, an investigational, oral, first-in-class compound that inhibits the anaplastic lymphoma kinase, or ALK, at the International Association for the Study of Lung Cancer's 14th World Conference on Lung Cancer, July 3-7 in Amsterdam, The Netherlands.

28 Jun 2011

Stresses can change gene expression without DNA sequence change

None of us are strangers to stress of various kinds. It turns out the effects of all those stresses can change the fate of future generation, influencing our very DNA without any change to the underlying sequence of As, Gs, Ts and Cs. Now, researchers reporting in the June 24th issue of Cell, a Cell Press publication, have new evidence that helps to explain just how these epigenetic changes really happen.

24 Jun 2011

New research helps explain how memories are stored at synapses

Have a tough time remembering where you put your keys, learning a new language or recalling names at a cocktail party? New research from the Lisman Laboratory at Brandeis University points to a molecule that is central to the process by which memories are stored in the brain. A paper published in the June 22 issue of the Journal of Neuroscience describes the new findings.

24 Jun 2011

Millennium reports ongoing MLN8237 Phase II study results on non-Hodgkin lymphoma

Millennium: The Takeda Oncology Company today announced the presentation of results from an ongoing Phase II study of MLN8237, an investigational Aurora A kinase inhibitor, in patients with relapsed/refractory aggressive B-cell and T-cell non-Hodgkin lymphoma.

24 Jun 2011

TESARO secures $101M in Series B financing

TESARO, Inc., an oncology-focused biopharmaceutical company, today announced that it has secured $101 million in a Series B financing to advance and expand the Company's cancer product portfolio.

21 Jun 2011

Placental growth factor also plays a role in chronic myeloid leukemia

Chronic myeloid leukemia (CML) is a particular form of leukemia or cancer of the bone marrow, which can be treated with targeted imatinib. However, in some cases this medicine has no effect. Researchers at the VIB Vesalius Research Centre, K.U. Leuven, under the direction of Peter Carmeliet, have investigated the role of placental growth factor (PlGF) in mice with CML.

15 Jun 2011

QIAGEN to acquire Ipsogen

QIAGEN N.V. has made an offer and entered into exclusive negotiations to purchase a 47% initial stake in Ipsogen S.A. and subsequently make a public offer to fully acquire a global leader in molecular profiling and personalized healthcare diagnostics for a broad range of hematological cancers.

From QIAGEN Manchester Limited 15 Jun 2011

Researchers investigate the role of PlGF in mice with chronic myeloid leukemia

14 Jun 2011

FDA clears Mitsubishi's PATHFAST cardiac Troponin I diagnostic test

Mitsubishi Chemical Medience Corporation announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) premarketing notification clearance to the PATHFAST cTnI-II diagnostic test, clearing the way for its sale in the United States.

14 Jun 2011

Astellas, Ambit Biosciences announce interim results from AC220 Phase 2 trial against AML

Ambit Biosciences Corporation and Astellas Pharma Inc. announced today results from a planned interim analysis in an ongoing Phase 2 study evaluating AC220, a potent and selective FLT3 inhibitor.

14 Jun 2011

Oncogene Aurora A may contribute to polycystic kidney disease

The Aurora A kinase may contribute to polycystic kidney disease (PKD) by inactivating a key calcium channel in kidney cells, according to a study in the June 13 issue of The Journal of Cell Biology.

13 Jun 2011